EGFR-activating mutations are not present in breast tumors of Japanese patients

Anticancer Research

Volumn 30, Issue 10, 2010, Pages 4219-4222

  Uramoto, Hidetaka ^a   Shimokawa, Hidehiko ^a   Nagata, Yoshika ^a   Ono, Kenji ^a   Hanagiri, Takeshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Breast cancer; EGFR; Mutation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST SURGERY; BREAST TUMOR; CANCER SURGERY; EXON; FEMALE; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENZYME ACTIVATION; FEMALE; HUMANS; JAPAN; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650232757     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP and Cardoso F; ESO-MBC Task Force: International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? J Natl Cancer Inst 102: 56-63, 2010.
2. Murphy CG and Fornier M: HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 24: 410-415, 2010.
3. Druker BJ: Translation of the Philadelphia chromosome into therapy for CML. Blood 112: 4808-4817, 2008.
4. Uramoto H and Mitsudomi T: Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer 96: 857-863, 2007.
5. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M and Yasumoto K: Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51: 71-77, 2006.
6. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN Jr., Coltman CA Jr., Fukuoka M, Saijo N, Fukushima M and Mack PC: Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J Clin Oncol 27: 3540-3546, 2009.
7. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T and Yasumoto K: Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol 5: 1136-1142, 2010.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
9. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 18: 1027-1033, 2005.
10. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, Carvalho S, Savage K, Simpson PT, Jones C, Swift S, Mackay A, Reis RM, Hornick JL, Pereira EM, Baltazar F, Fletcher CD, Ashworth A, Lakhani SR and Schmitt FC: EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 209: 445-53. 2006.
11. Japanese Breast Cancer Society: General rules for clinical and pathological recording of breast cancer. Breast Cancer 12: S12-14, 2005.
12. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive Molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-RAS, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
13. Uramoto H, Uchiumi T, Izumi H, Kohno K, Oyama T, Sugio K and Yasumoto K: A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. Anticancer Res 27: 2297-303, 2007.
14. Normanno N, De Luca A, Maiello MR, Mancino M, D'Antonio A, Macaluso M, Caponigro F and Giordano A: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. Front Biosci 10: 2611-2617, 2005. (Pubitemid 40905265)
15. Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, Plass C, Caldes T, Mutter GL, Villalona-Calero MA and Eng C: Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer 92: 1922-1926, 2005.
16. Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P and Harris AL: EGFR mutations in exons 18-21 in sporadic breast cancer. Ann Oncol 18: 203-5, 2007.
17. Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T and Yasumoto K: A resistance to gefitinib. Int J Clin Oncol 11: 487-491, 2006.
18. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
19. Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, Onitsuka T and Yasumoto K: Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27: 411-417, 2009.
20. Nose N, Uramoto H, Iwata T, Hanagiri T and Yasumoto K: Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer in press.
21. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR and Siegfried JM: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65: 1459-1470, 2005.
22. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte SM and Siegfried JM: Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 64: 51-59, 2009.
23. Dubey S, Siegfried JM and Traynor AM: Non-small cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 7: 416-424, 2007.
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
25. Moasser MM: Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26: 6577-6592, 2007.
26. Anido J, Matar P, Albaneil J, Guzmán M, Rojo F, Arribas J, Averbuch S and Baselga J: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9: 1274-1283, 2003.
27. Agrawal A, Gutteridge E, Gee JM, Nicholson RI and Robertson JF: Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 12: S135-S144, 2005.